How Does bYlok® Technology Work And How Can It Improve Bispecific Production?

Bispecific antibodies offer numerous potential clinical benefits, and the number of bispecifics in development continues to soar. However, production of these molecules can present challenges such as heavy-light chain mispairing, affecting yields of the correct species, downstream processing workloads, COGs and timelines.

In this animation video, we cover how bYlok® technology works, how it can drive correct heavy-light chain pairing to >95%, and how you can access it via a license agreement to enable you to overcome industry-wide challenges in bispecific production.